Targeting the EGFR signalling pathway in metastatic colorectal cancer

An excellent review👇

The Lancet Gastroenterology & Hepatology
thelancet.com/journals/langa…

Best way to stay updated in oncology! 👇✅👏🏻

Taking a pancreatic tumor for a spin using CODA.

Using the AI-based CODA workflow, we map a pancreatic tumor and its microenvironment at single-cell resolution.

Key advantages: 3D, huge sample volume, multiple labels, easy multiplexing, single-cell.

nature.com/articles/s4158…

The OncoAlert 🚨Network Warmly extends its congratulations to Two of our Distinguished Faculty, part of our Founding faculty and ESMO - Eur. Oncology Presidents:

⚕️ Solange Peters 🇨🇭 from CHUV / Centre hospitalier universitaire vaudois
⚕️ FabriceAndre 🇫🇷 from Gustave Roussy

Named Giants of Cancer Care, an award that…

Stay informed about important developments in oncology treatment! 🔬

Save this post to keep track of essential milestones and regulatory approvals in cancer care.

Learn more here: bit.ly/3v0joFa 💫

#OncologyUpdates #RegulatoryNews #CancerResearch #LARVOL

➡️Local recurrence of endometrial cancer
☢️Planned definitive radiotherapy
💉Should concurrent weekly cisplatin be added ❓
NRG Oncology/GOG trial Journal of Clinical Oncology

❌Negative study
➡️Longer PFS with radiation mPFS: not reached for RT vs 73 months for chemoradiation, HR: 1.25 (95% CI,

We used CODA to digitally register thousands of serial H&E sections and to track microscopic PanIN lesions using a deep learning segmentation algorithm.

I’m beyond excited to share work from my PhD, co-led with Alicia Braxton, out today in Nature! We used CODA to map the anatomic and genomic properties of pancreatic cancer precursors. Led by the amazing Laura DeLong Wood and Denis Wirtz !

nature.com/articles/s4158…

🗓️Roundup of the last year-Practice changing trials: Breast cancer 🔅

✅Early stage

➡️HR(+)
✔️monarchE
✔️NATALEE

➡️HER2(+)
✔️KATHERINE

➡️TNBC
✔️KEYNOTE-522

✅Advanced stage

➡️HR(+)
✔️MONARCH 3
✔️PARSIFAL-LONG
✔️SONIA
✔️INAVO120
✔️EMERALD
✔️CAPItello-291
✔️DESTINY-Breast04

The OncoAlert🚨NEWSLETTER OUT
Covering April 25 to May 1, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

COVERING
✅DESTINY-Breast06
✅Monarch E🦋
✅ US Preventive S Task force #BreastCancer Screen
✅ U.S. FDA 🇺🇸approval of Tisotumab vedotin
✅NEO

Just Out by OUR AMAZING OncoAlert 🚨Faculty
Emre Yekedüz , Yüksel Ürün 🇹🇷and team Sati Coskun Yazgan, Erman Akkus

Thromboembolic Risk in #ProstateCancer Patients Treated with PARP Inhibitors

Meta-analysis of phase II and phase III clinical trials examining the use of poly…

⁉️Survival vs. life quality is always questioned in metastatic cancer patients⁉️

➡️ P3 TOPAZ-1 study, durvalumab plus gemcitabine and cisplatin was associated with significant improvements in overall survival compared with placebo, gemcitabine, and cisplatin in pts with advanced

Our new study Prostate Cancer and PARPi - Erman Akkus

oncodaily.com/59593.html

Coskun YAZGAN Emre Yekedüz Yüksel Ürün Critical Reviews in Oncology Hematology (CROH) ESOncology International Society of Liquid Biopsy Elsevier Prostate Cancer UK World Thrombosis Day Thrombosis UK Ankara Tıp Fakültesi

#oncodaily #oncology #cancer …

📢📗
Merkel-cell carcinoma guideline of ESMO - Eur. Oncology and EURACAN

✅Management of locaregional and advanced/metastatic disease

👉doi.org/10.1016/j.esmo…

ESMO Open EADV Türk Dermatoloji Derneği The Skin Cancer Foundation 👒 Enes Erul MD Beliz Bahar Karaoğlan
OncoAlert OncoDaily
#cancer #oncology #skin #MedX

Extremely proud to announce that our NEOPREDICT-Lung study on neoadjuvant PD-1 and LAG-3 inhibition in resectable NSCLC is now online in Nature Medicine . Without any doubt one the highlights of my career so far.
nature.com/articles/s4159…

🧵 Just published: USPSTF recommends all women undergo routine #breastcancer screening every other year beginning at age 40, an update from the 2016 recommendation to start at age 50.

ja.ma/3WmvqEO

#Perihilar #cholangiocarcinoma #livertransplantation #outcome #MedEd
🔥 Perspective: Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?
📚 Read more: lnkd.in/gW3_m-hJ
📗 Hope this will be an interesting reading!